Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
Breye's oral candidate danegaptide demonstrates a favorable safety profile and clinical activity in non-proliferative diabetic retinopathy (NPDR). This promising data could advance its development in a critical area of eye health.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.